The FDA has expanded the approval of vemurafenib (Zelboraf) to include the treatment of Erdheim–Chester disease in adult BRAF V600–positive patients. This marks the first approval from the agency for treating this rare blood cancer.
In patients with chronic myeloid leukemia treated with bosutinib who were resistant or intolerant to previous tyrosine kinase inhibitors, health-related quality of life was well maintained over the long term.
About one in every 25 patients with chronic lymphocytic leukemia had abnormal liver function tests, and one in four developed liver dysfunction within 10 years, according to the results of a retrospective study.
Survival of patients with myelofibrosis who undergo splenectomy is adversely affected by older age, the need for transfusion, and leukocyte and circulating blast cell counts, according to a new analysis.
Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.
Non-Hodgkin lymphoma patients who have preexisting cardiovascular risk factors are at an increased risk of heart failure and are often prescribed anthracyclines less frequently, according to a large population-based study.